Chemomab Therapeutics Ltd. (CMMB)
NASDAQ: CMMB · Real-Time Price · USD
1.490
+0.015 (1.02%)
Apr 29, 2026, 12:44 PM EDT - Market open
Chemomab Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Cash & Equivalents | 7.56 | 6.07 | 9.29 | 13.52 | 15.19 | Upgrade
|
| Short-Term Investments | 2.8 | 8.2 | 10.49 | 26.37 | 45.98 | Upgrade
|
| Cash & Short-Term Investments | 10.37 | 14.27 | 19.78 | 39.89 | 61.16 | Upgrade
|
| Cash Growth | -27.34% | -27.89% | -50.41% | -34.77% | 422.83% | Upgrade
|
| Other Receivables | 0.2 | 0.26 | 0.29 | 0.46 | 0.18 | Upgrade
|
| Receivables | 0.2 | 0.26 | 0.29 | 0.46 | 0.18 | Upgrade
|
| Prepaid Expenses | 2.86 | 1.44 | 0.75 | 1.31 | 1.35 | Upgrade
|
| Restricted Cash | - | 0.08 | 0.08 | 0.08 | - | Upgrade
|
| Total Current Assets | 13.43 | 16.04 | 20.9 | 41.74 | 62.69 | Upgrade
|
| Property, Plant & Equipment | 0.18 | 0.54 | 0.7 | 0.59 | 0.7 | Upgrade
|
| Other Long-Term Assets | 0.21 | 0.39 | 0.56 | 0.73 | 0.96 | Upgrade
|
| Total Assets | 13.81 | 16.96 | 22.15 | 43.06 | 64.35 | Upgrade
|
| Accounts Payable | 0.49 | 0.63 | 0.52 | 1.69 | 1.34 | Upgrade
|
| Accrued Expenses | 0.99 | 2.47 | 4.25 | 4.94 | 1.21 | Upgrade
|
| Current Portion of Leases | - | 0.12 | 0.08 | 0.12 | 0.11 | Upgrade
|
| Total Current Liabilities | 1.48 | 3.22 | 4.84 | 6.75 | 2.65 | Upgrade
|
| Long-Term Leases | - | 0.21 | 0.32 | 0.09 | 0.24 | Upgrade
|
| Total Liabilities | 1.48 | 3.43 | 5.15 | 6.84 | 2.89 | Upgrade
|
| Additional Paid-In Capital | 123.95 | 116.16 | 105.68 | 101.26 | 97.64 | Upgrade
|
| Retained Earnings | -111.62 | -102.62 | -88.68 | -63.82 | -36.17 | Upgrade
|
| Treasury Stock | - | - | - | -1.22 | - | Upgrade
|
| Total Common Equity | 12.33 | 13.54 | 17 | 36.22 | 61.47 | Upgrade
|
| Shareholders' Equity | 12.33 | 13.54 | 17 | 36.22 | 61.47 | Upgrade
|
| Total Liabilities & Equity | 13.81 | 16.96 | 22.15 | 43.06 | 64.35 | Upgrade
|
| Total Debt | - | 0.32 | 0.39 | 0.21 | 0.34 | Upgrade
|
| Net Cash (Debt) | 10.37 | 13.94 | 19.39 | 39.68 | 60.82 | Upgrade
|
| Net Cash Growth | -25.65% | -28.10% | -51.13% | -34.76% | 439.64% | Upgrade
|
| Net Cash Per Share | 1.63 | 3.11 | 6.60 | 13.95 | 23.45 | Upgrade
|
| Filing Date Shares Outstanding | 7.19 | 4.71 | 3.55 | 2.76 | 2.85 | Upgrade
|
| Total Common Shares Outstanding | 7.19 | 4.71 | 3.55 | 2.76 | 2.85 | Upgrade
|
| Working Capital | 11.95 | 12.82 | 16.06 | 34.99 | 60.04 | Upgrade
|
| Book Value Per Share | 1.71 | 2.87 | 4.79 | 13.11 | 21.56 | Upgrade
|
| Tangible Book Value | 12.33 | 13.54 | 17 | 36.22 | 61.47 | Upgrade
|
| Tangible Book Value Per Share | 1.71 | 2.87 | 4.79 | 13.11 | 21.56 | Upgrade
|
| Machinery | 0.47 | 0.5 | 0.5 | 0.5 | 0.43 | Upgrade
|
| Leasehold Improvements | - | 0.01 | 0.01 | 0.02 | 0.02 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.